The disclosure is genuinely good
The compounding pharmacy is named in the FAQ, again on the privacy page under its own heading, and a third time in the Terms under a heading reading partnering pharmacy. Twenty-six of the ninety-five sellers here name a pharmacy at all, and naming the same one consistently across three documents is rarer still.
Every price is a three-month plan, and the plan total is printed beside the per-month figure in the same card. Divide one by the other and it comes out exactly, which is the disclosure that separates a monthly charge from a prepayment divided down. The card also says every dose level is included and that the rate is locked for the life of the plan.
Coverage is stated twice, in two documents. The FAQ answers the states question with a fifty-state claim and adds that prescriptions are written by clinicians licensed in your own state. The Terms repeat it under a heading of its own. Fifty-eight of the ninety-five sellers here publish no service area at all, so a plain answer in two places is worth something.
The membership claim is the cleanest thing on the page. It is not a slogan; it is a cell in a comparison table, against four named rivals with their own membership figures beside it. Forty-one of the ninety-five sellers here charge no membership, and this is one of the few that makes the claim in a form you can check against somebody else.
The clause about what you may say afterwards
Under a heading covering public statements and reviews, the Terms ask patients to agree not to publish, post or disseminate any false, misleading or defamatory statements about the practice entity, its providers, affiliates or partner pharmacies. It adds that honest, good-faith feedback is welcome and that knowingly posting false or malicious content with intent to harm will be treated as defamation and business interference.
The carve-out for good-faith feedback is real and it is worth noting. So is the fact that the seller is the party deciding, in the first instance, which side of that line a review falls on — and that the agreement is a precondition of receiving the medication.
We are recording this as a fact about the document, not a verdict on it. Read the clause before you accept it, and know that it extends past the company to its clinicians and its pharmacy.
Two corporate forms for one company
The FAQ is unusually specific about who this is: it names a limited liability company, states the formation state, gives the formation year, and goes out of its way to say it has no relationship with two similarly named companies. That is a better identity disclosure than most sellers here manage.
Every page footer then carries a copyright line naming a corporation instead. Two different corporate forms, one brand, on the same site. It may be a stale footer or a restructuring; the site does not say which.
A third entity appears only inside the non-disparagement clause: a professional limited liability company named as the practice. The Terms elsewhere say telemedicine is delivered via a named provider network. So the company you contract with, the practice you agree not to criticise and the network your clinician comes from are three different names, and only one of them is on the front of the site.
The evidence behind the headline number
The homepage leads with a weight-loss comparison. Its footnote describes self-reported data from roughly six hundred members who reported their own weight at intake and every three to four weeks after, set against outcomes from a single cited journal reference.
Self-reported weights from a seller's own subscribers are the weakest form of outcome evidence there is, for the ordinary reason that the people who keep reporting are the people for whom it is working. The footnote is honest about the method, which is more than several sellers here manage — but the method is what it is.
No individual clinician is named anywhere on the pages we read. The Terms name a provider network instead and say it maintains licensed clinicians across all fifty states. Fifty-one of the ninety-five sellers here name nobody who prescribes.
What a careless price scrape would get wrong here
This is worth a paragraph because it is a trap. The priced page carries a comparison table with four named competitors, and each competitor column prints a starting monthly figure and a membership fee. Six starting figures appear on the page. Only two of them are this seller's.
Any tool that matched a currency pattern per element and attributed the results to the page it was on would have recorded four rival prices as WeightlessRx prices, and three of them are higher. Our record carries exactly two price rows for this seller.
The competitor figures are also worth reading as what they are: this seller's characterisation of four rivals, quoted without a date or a source. We did not verify them and they are not on this roster as anything.
WeightlessRx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $167/moPer month on a three-month plan, with the total printed beside it: "Semaglutide / From $167 / mo / $500 total · 3-month supply · every dose included / Lock in your price for life". The FAQ repeats it: "Semaglutide starts at $167/month on the 3-month plan ($500 total) ... There is no membership fee, no consult fee, and shipping is free." | September 2026source |
| Tirzepatide (compounded) | $233/moPer month on a three-month plan, total printed: "Tirzepatide / From $233 / mo / $700 total · 3-month supply · every dose included / Lock in your price for life". ⚠ $700 ÷ 3 = $233.33, so the per-month figure is the prepaid total divided down rather than a monthly charge. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 95 providers reviewed here are paid partners today; the other 91 are not. See how this works.
See WeightlessRx's current price →Good fit if
- Readers who want the compounding pharmacy named, and named the same way in three separate documents.
- Buyers who want the prepaid total printed beside the per-month figure so they can see which is which.
- People who want a fifty-state footprint stated under a heading in the Terms rather than implied.
- Anyone who wants a zero membership fee shown as a checkable claim rather than a marketing line.
- Readers who like being told the card is authorised but not charged until a clinician approves them.
Look elsewhere if
- Anyone unwilling to accept a clause asking them not to publish statements about the practice, its providers or its pharmacy that the seller judges false or misleading.
- Readers who want the prescribing clinician named. A network is named; no person is.
- Buyers who want a month-to-month option. Every published figure here is a three-month plan.
- Anyone who wants outcome claims backed by something other than the seller's own members reporting their own weights.
- Readers who need one consistent legal entity. The FAQ names a limited liability company and every footer names a corporation.
How this review was verified
- Re-read the homepage, the privacy page and the Terms on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller.
- Separated this seller's two prices from the four competitor figures in its own comparison table, rather than taking every currency match on the page. A per-element price scrape here would have recorded four rivals' rates as this seller's.
- Checked the arithmetic on both plans: each printed total divided by three gives the printed per-month figure, which is why our record describes them as prepayments rather than monthly charges.
- Confirmed the pharmacy name appears in three separate documents rather than once, and recorded the practice entity and the provider network separately because they are different names.
- Read the Terms in full and quoted the public-statements clause as written, including its carve-out for honest, good-faith feedback.
- Recorded the two corporate forms the site uses for itself without choosing between them, because the site does not.
- Printed the status, byte size and effective URL of every fetch, compared the effective path to the requested one, and ran a nonsense path against this host in the same run, which returned 404.
- Screened both corporate forms, the brand name and the practice entity against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. None returned a letter; untitled letters are published separately and were not searched.